Overview

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Status:
Completed

Trial end date:
2018-01-24

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in HIV-1 infected participants.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Anti-Retroviral Agents
Cobicistat
Lamivudine